News | FFR Technologies | October 05, 2015

Beaumont First in Michigan to Introduce Noninvasive Diagnostic Chest Pain Tool

FFR-CT technology from HeartFlow reveals 99 percent blockage in left anterior descending artery of 65-year-old patient

Beaumont Hospital Royal Oak, first in Michigan, FFR-CT, HeartFlow Inc., heart failure

Image courtesy of HeartFlow Inc.

October 5, 2015 — Beaumont Hospital - Royal Oak is the first in Michigan and one of just a handful in the United States to offer fractional flow reserve by computed tomography, also known as FFR-CT. The technology is a noninvasive, diagnostic tool recently approved by the U.S. Food and Drug Administration (FDA) and developed by HeartFlow Inc.

Heart disease is the leading killer of men and women in the United States. In 2008, the last year for which statistics are available, more than 5 million Americans required emergency center care for chest pain and more than 16 million Americans required subsequent testing, according to the American Heart Association. As a result, 1 million invasive cardiac catheterizations were performed in 2008 throughout the nation for diagnostic purposes alone.

“Up to half of all diagnostic heart catheterizations in the United States reveal no significant coronary artery disease,” says Gil Raff, M.D., director of cardiac MRI (magnetic resonance imaging) and CT at Beaumont Hospital - Royal Oak, leading the implementation of HeartFlow technology. “FFR-CT gives us the individual patient information we need without having to perform an invasive procedure. This means we are able to reduce costs, along with the risk of radiation exposure and possible patient complications.”    

HeartFlow’s FFR-CT is a Web-based software that analyzes existing coronary angiography images to provide physicians with detailed data about blood flow within the coronary arteries. It uses a standard noninvasive coronary CT angiography scan, uploaded to the cloud, and combines it with proprietary computer algorithms to create a three-dimensional model of the patient’s coronary arteries, that can determine whether any given plaque requires cardiac catheterization.  

HeartFlow enables Beaumont to take its focus on noninvasive diagnosis of heart disease a major step forward, said Beaumont Hospital – Royal Oak interventional cardiologist Justin Trivax, M.D.

“Beaumont researchers have been leading the charge in noninvasive chest pain diagnostics with coronary computed tomographic angiography, commonly referred to as CTA, for the last decade,” Trivax said. “To that end, we’ve been able to ‘rule out’ coronary artery disease for many patients who have chest pain.

“But CCTA has limited usage for certain patients and in these cases, cardiac catheterization has been the best and most accurate diagnostic tool available,” Trivax explained. “Even with newer techniques, smaller catheters and better drugs which reduce the risk of stroke and bleeding, all procedures have some inherent risk. HeartFlow FFR-CT enables us to eliminate that risk for many patients.”

It also extends the noninvasive benefit of coronary CCTA to more high-risk and complex cases, Raff said.

Trivax’s patient, Jerry Tolle, 65, of West Bloomfield was among the first to experience the new technology.

A fitness aficionado who worked out three to four times a week using free weights and cardiovascular equipment at his local gym, both Tolle and Trivax were surprised when Tolle began experiencing chest pain. 

Tolle’s disease trajectory was atypical, according to Trivax.

“Mr. Tolle underwent stress testing but the results were not definitive. The EKG portion was abnormal but the imaging portion was normal. There wasn’t enough data to proceed with an invasive procedure at that time,” Trivax said.

Even so, Tolle failed aggressive medical therapy and complained of burning in his chest after eating. CCTA was performed and HeartFlow analysis revealed that Tolle’s left anterior descending artery — commonly known as ‘the widow maker’ — was 99 percent blocked. A stent was implanted via a heart catheterization procedure and after a few weeks’ rest, Tolle has started cardiac rehabilitation, three times a week and is doing well.

“It’s good to know that had the results not indicated a blockage, an invasive procedure would not have been necessary,” Tolle said.  “I’m not totally myself yet, but I’m back to work and feeling better each day.

“In fact,” he said, “I’ll probably get bored with rehab before I’ve finished the program – it’s significantly less intense than my previous work out.” 

For more information: www.heartflow.com

Related Content

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

News | FFR Technologies | July 09, 2020
July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II
The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

Feature | FFR Technologies | July 07, 2020 | Dave Fornell, Editor
An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

News | FFR Technologies | May 15, 2020
May 15, 2020 – A late-breaking study aimed to evaluate whether...
In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image.

In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image. 

Feature | FFR Technologies | August 05, 2019 | Dave Fornell and Greg Freiherr
New technologies have been developed that may replace the traditional pressure wires and adenosine to assess the...
First Prospective Registry Confirms FFR Impacts CAD Treatment Plans
News | FFR Technologies | June 17, 2019
A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans...
One in Four Patients Have Residual Ischemia Following PCI
News | FFR Technologies | March 20, 2019
At the American College of Cardiology’s (ACC) annual meeting, March 16-18 in New Orleans, Philips announced the results...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | FFR Technologies | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. Abbott FFR.

Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. 

Technology | FFR Technologies | March 06, 2019
March 5, 2019 –  The U.S.
CathWorks FFRangio System Receives U.S. FDA Clearance
Technology | FFR Technologies | December 21, 2018
CathWorks announced that its FFRangio System received U.S. Food  and Drug Administration (FDA) 510(k) clearance. The...